Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Neurosciences Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,167,673

243 payments

Through program year 2025, Advanced Neurosciences Research LLC is reported as receiving $2,167,673 in research payments, across 243 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$150,011	39
2024	Research	$320,333	25
2023	Research	$269,773	37
2022	Research	$285,681	21
2021	Research	$446,552	44
2020	Research	$665,361	68
2019	Research	$29,962	9

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $1,009,565 45 payments
AbbVie, Inc. $800,000 88 payments
Alexion Pharmaceuticals, Inc. $176,576 16 payments
EMD Serono, Inc. $78,064 53 payments
F. Hoffmann-La Roche AG $59,810 17 payments
Roche Products Limited $21,663 12 payments
Mallinckrodt Enterprises LLC $10,077 5 payments
H. Lundbeck A S $6,654 4 payments
Mallinckrodt Hospital Products Inc. $3,915 2 payments
Pfizer Inc. $1,350 1 payment

Studies the money was for Research payments · program years 2019–2025

Ocrelizumab RMS High Dose Study $790,063 17 payments
M18-918 $306,680 12 payments
M14-397 $197,522 12 payments
Evaluation of Fenebrutinib in RMS Patients $131,418 16 payments
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) $97,987 7 payments
Ocrelizumab PPMS High Dose Study $77,834 10 payments
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $65,698 17 payments
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis $56,961 8 payments
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) $48,802 4 payments
Second Phase III in RMS $44,642 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.